

Marquette University

e-Publications@Marquette

Biomedical Sciences Faculty Research and
Publications

Biomedical Sciences, Department of

3-1-1988

Fibrinogen Birmingham: A Heterozygous Dysfibrinogenemia ($A\alpha$ 16 Arg \rightarrow His) Containing Heterodimeric Molecules

Kevin R. Siebenlist

Marquette University, kevin.siebenlist@marquette.edu

J. T. Prchal

University of Wisconsin Medical School

Michael W. Mosesson

Blood Center of Wisconsin

Follow this and additional works at: https://epublications.marquette.edu/biomedsci_fac



Part of the [Neurosciences Commons](#)

Recommended Citation

Siebenlist, Kevin R.; Prchal, J. T.; and Mosesson, Michael W., "Fibrinogen Birmingham: A Heterozygous Dysfibrinogenemia ($A\alpha$ 16 Arg \rightarrow His) Containing Heterodimeric Molecules" (1988). *Biomedical Sciences Faculty Research and Publications*. 227.

https://epublications.marquette.edu/biomedsci_fac/227

Marquette University

e-Publications@Marquette

Biomedical Sciences Faculty Research and Publications/College of Health Sciences

This paper is NOT THE PUBLISHED VERSION.

Access the published version via the link in the citation below.

Blood, Vol. 71, No. 3 (March 1988): 613-618. [DOI](#). This article is © American Society of Hematology and permission has been granted for this version to appear in [e-Publications@Marquette](#). American Society of Hematology does not grant permission for this article to be further copied/distributed or hosted elsewhere without express permission from American Society of Hematology.

Fibrinogen Birmingham: A Heterozygous Dysfibrinogenemia (A α 16 Arg \rightarrow His) Containing Heterodimeric Molecules

K.R. Siebenlist

Mount Sinai Medical Center. University of Wisconsin Medical School. Milwaukee Clinical Campus

The Department of Pathology, University of Alabama at Birmingham

J.T. Prchal

Mount Sinai Medical Center. University of Wisconsin Medical School. Milwaukee Clinical Campus

The Department of Pathology, University of Alabama at Birmingham

M.W. Mosesson

Mount Sinai Medical Center. University of Wisconsin Medical School. Milwaukee Clinical Campus

The Department of Pathology, University of Alabama at Birmingham

Abstract

Fibrinogen was isolated from the plasma of a 25-year-old female with a history of mild bleeding and several recent moderate to severe hemorrhagic episodes. Coagulability with thrombin approached 100% and varied directly with the time of incubation with the enzyme. High-performance liquid chromatography analysis of thrombin-induced fibrinopeptide release demonstrated retarded fibrinopeptide A (FPA) and fibrinopeptide B (FPB) release and the presence of an abnormal A peptide (FPA*) amounting to 50% of the total. The same biochemical abnormalities were found in her asymptomatic father. Amino acid analysis and carboxypeptidase digestion of FPA* demonstrated the substitution of His for Arg at A α 16. In contrast to the thrombin- and reptilase-sensitive Arg-Gly bond in the normal A α chain, the abnormal A α chain (A* α) sequence is resistant to reptilase attack but is slowly cleaved by thrombin. To evaluate whether Birmingham A* α and A α chains had been assembled nonselectively into heterodimeric (ie, 50% A α , A* α) and homodimeric (ie, 25% A α , A α ; 25% A* α , A* α) species, the clot and the clot liquor resulting from reptilase treatment of normal or Birmingham fibrinogen were separated, and each was then further incubated with thrombin to release remaining fibrinopeptides. Assuming that fibrinogen Birmingham contained heterodimeric molecules and that these and the normal molecules were completely incorporated into a reptilase clot, the expected coagulability would be 75%. In addition, subsequent thrombin treatment of the reptilase clot would release 50% of the total FPA* and 75% of the total FPB present in the original sample. On the other hand, if only homodimeric fibrinogen species (50% A α , A α ; 50% A* α , A* α) existed, the maximum reptilase coagulability would be 50%, and after thrombin treatment, 50% of the total FPB and no FPA* would be recovered from the reptilase clot. We found the propositus's fibrinogen to be 68% coagulable, and we recovered 45% of the FPA* and 70% of the FPB from the reptilase clot. Essentially the same coagulability and distribution of fibrinopeptides was found in the reptilase clot from her father's fibrinogen. We therefore conclude that fibrinogen Birmingham contains heterodimeric species (A α , A* α) amounting to approximately 50% of the circulating fibrinogen molecules. The existence of heterodimers is consistent with a nonselective intracellular process of constituent chain assembly of dimeric plasma fibrinogen molecules.

Introduction

Congenital Dysfibrinogenemia is a disorder of fibrinogen synthesis in which a structural abnormality results in altered functional characteristics of the protein. To date, such fibrinogen molecules exhibit either altered fibrinopeptide release or defective fibrin polymerization.^{1, 2, 3} Several amino acid exchanges in the vicinity of the A α Arg 16 Gly 17 cleavage site are now known to affect the interaction between thrombin and fibrinogen and the rate of fibrinopeptide release.² The A α 16 Arg \rightarrow His substitutions are the most common and include homozygous fibrinogens Bicetre³ and Giessen^{4, 5} and heterozygous fibrinogens New Albany,² Petoskey,^{6, 7} Manchester,^{8, 9, 10} Louisville,¹¹ Sydney I,¹² Bern II,¹³ Seattle II,¹⁴ Amiens I, Amiens II,¹⁵ and Bergamo III.¹⁶

In the case of the A α 16 Arg \rightarrow His substitution, heterozygous members of reported families have had little or no clinically significant hemostatic disorders.^{6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16} Similarly, heterozygous A α 16 Arg \rightarrow Cys family members are likewise free of hemostatic disorders.^{16, 17, 18, 19, 20, 21} In contrast, homozygous A α 16 Arg \rightarrow His and A α 16 Arg \rightarrow Cys individuals have a history of significant hemorrhagic episodes.^{3, 4, 5, 22, 23} This suggests that in heterozygous individuals fibrin formation is not sufficiently compromised to result in a bleeding tendency.

It is well recognized that reptilase does not cleave the abnormal A α chains (A* α) of fibrinogens containing an A α 16 Arg \rightarrow His substitution, although fibrinopeptide A containing histidine at position 16 (FPA*) can be released from A* α chains slowly and completely by thrombin.^{6, 7, 8, 11} Galanakis et al¹¹ studied fibrin(ogen) Louisville from which FPA had been released by reptilase treatment. They found that all FPA*-containing fibrinogen molecules were in the incoagulable reptilase clot liquor. Because reptilase cleavage of FPA from hybrid species should have resulted in significant incorporation of half-activated A* α , α fibrin molecules into the reptilase clot, they therefore concluded that fibrinogen Louisville contained only homodimeric species (ie, A α , A α or A* α , A* α). Hybrid molecular species (ie, A α , A* α) would be expected to occur if intracellular fibrinogen chain assembly were a nonselective process. Thus, their observation suggests that there is selective intracellular association of constituent A α subunit chains during hepatic assembly of Louisville fibrinogen dimers. In this study, we examined the question of homodimers v heterodimers in fibrinogen prepared from a newly discovered family with an A α 16 Arg \rightarrow His substitution (fibrinogen Birmingham). This fibrinogen is accompanied in the propositus by moderate to severe bleeding episodes.

MATERIALS AND METHODS

Tris and glycine were obtained from Aldrich Chemical Co, Milwaukee. Phenylmethylsulfonyl fluoride, orthophthalaldehyde (OPA), carboxypeptidase A (CPA), carboxypeptidase B (CPB), and reptilase (Atroxin) were purchased from Sigma Chemical Co, St Louis. Trasylol (aprotinin) was from Mobay Chemical Corp, New York. Reagents for amino acid analysis were purchased from Varian Instrument Group, Sunnyvale, CA. Human thrombin was a generous gift from Dr J Fenton III (Division of Laboratories and Research, New York State Department of Health, New York). All other reagents were of the highest purity available from commercial sources.

Normal fibrinogen fraction 1–2 (from pooled normal plasma) and fibrinogen Birmingham fraction 1–2 were isolated from citrated plasma by glycine precipitation²⁴ and further purified as described by Mosesson and Sherry.²⁵ Fibrinogen concentrations were determined spectrophotometrically at 280 nm by using an absorbance coefficient ($A_{1\text{cm}}^{1\%}$) of 15.1 for fibrinogen.²⁶

Clinical coagulation studies were performed by standard methods at the University of Alabama Hospitals in Birmingham. Multimeric analysis of von Willebrand factor (vWf) was performed at the Blood Center of Southeastern Wisconsin by electrophoresis of plasma in 0.65% Seakem high gelling temperature ultra pure agarose gels (HGT-(P); FMC Corp, Rockland, ME) in the presence of 0.1% sodium dodecyl sulfate (SDS) and visualized by using radiolabeled rabbit antihuman vWf and autoradiography as previously described.²⁷ The reference standard for vWf assays was pooled plasma from 50 normal donors (stored at -80°C).

Thrombin time measurements were made in a Fibrometer Precision Coagulation Timer (BBL, Cockeysville, MD) by adding 0.1 mL human thrombin at a concentration of 4 National Institutes of Health U/mL to 0.3 mL fibrinogen in 50 mmol/L Tris and 120 mmol/L NaCl, pH 7.4. Clottability of the purified fibrinogens was determined as described by Laki.²⁸

SDS-polyacrylamide gel electrophoresis (PAGE) was performed by the method of Laemmli²⁹ on 9% slab gels.

Kinetics of fibrinopeptide release were analyzed by incubating fibrinogen (3 mg/mL) in 0.15 mol/L ammonium acetate buffer, pH 8.0, with human thrombin (0.2 U/mL) at room temperature for zero to 24 hours. Released fibrinopeptides were analyzed and quantified by using the high-performance liquid chromatography (HPLC) system described by Kehl et al and Kehl and Henschen.^{30,31} Specifically, the fibrinopeptides were detected at 215 nm with a Varian Vista model 5000 system controlled by a Varian model 401 microprocessor on an Altex Cl8 reverse-phase column (0.46 x 25 cm; Rainin Instrument Co, Woburn, MA) using a linear gradient of 12% to 28% acetonitrile in 25 mmol/L ammonium acetate, pH 6.0.

Fibrin monomer polymerization studies were performed by the method of Belitser et al,³² as modified by Galnick et al.³³ Fibrin monomer was prepared by treating fibrinogen (1 mg/mL) with thrombin (0.5 U/mL) in 0.06 mol/L KPO₄ buffer, pH 6.8, containing Trasylol (5 KIU/mL), for 18 hours at room temperature, winding the clot on a glass rod, and dissolving the clot in acetic acid (0.02 mol/L). Reaggregation was initiated by diluting an aliquot of the fibrin solution into at least a tenfold excess of 0.06 mol/L KPO₄ or 0.15 mol/L KPO₄ buffer, pH 7.0 (final). The final fibrin concentration was 0.5 mg/mL; polymerization was monitored at 350 nm in a Gilford model 240 spectrophotometer.

Normal FPA and Birmingham FPA and FPA* were isolated by HPLC as described earlier. Approximately 50 Mg of each was hydrolyzed under vacuum in 6 N HCl for 20 hours at 110°C. Released amino acids were identified and quantified by HPLC on a Varian MicroPak Hydrolysate column (0.4 x 15 cm) as recommended by Varian. Amino acids were reacted after fractionation with OPA³⁴ and detected with a Varian Fluorochrom Fluorescence Detector with an excitation filter of 340 to 380 nm and an emission filter of 390 nm.

CPA digestion was performed on the isolated fibrinopeptides by mixing the peptide (50 µg) in 0.2 mol/L N-ethylmorpholine acetate, pH 8.5, with CPA (15 µg) and incubating the mixture at 37°C for four hours. Digestion was terminated by lowering the pH to 2.5 to 3 by the addition of 5 mol/L acetic acid. After lyophilization, the released amino acids were detected and quantified as described earlier. CPB digestion was done under identical conditions using 0.072 enzyme commission units of CPB.

Fibrinogen Birmingham was examined for the presence of heterodimers as follows. Normal or Birmingham fibrinogen (3 mg/mL, 2 mL) in 0.15 mol/L ammonium acetate buffer, pH 8.5, was incubated with reptilase (1 U/mL) for two hours at room temperature. The resulting clots were wound on a glass rod, washed, and dissolved in 300 µl of 0.02 mol/L acetic acid. After determining the protein concentration, the fibrin solution was diluted into 1.5 mL of the ammonium acetate buffer containing thrombin (10 U/mL) and incubated at room temperature for two hours. An aliquot (200 to 400 µl) of the reptilase clot supernatant was saved for HPLC analysis. Solid ammonium sulfate (30% saturation wt/vol) was added to the remaining clot supernatant solution, the solution mixed at 4°C for 30 minutes, and the precipitate harvested by centrifugation. The precipitate was dissolved in 1 mL of the ammonium acetate buffer and treated with thrombin (10 U/mL) for two hours at room temperature. Released fibrinopeptides were detected in these samples by HPLC and quantified by comparison with recovery of FPA and fibrinopeptide B (FPB) from a thrombin-treated normal fibrinogen sample.

RESULTS

Case report. The propositus (C.D.) is a 25-year-old female from Birmingham, AL, who had experienced several relatively mild bleeding episodes since her childhood including protracted nosebleeds and

occasional hematomas. In the spring of 1984 she presented at the University of Alabama Hospitals with a hemarthrosis of her knee. Results of laboratory investigations (Table 1) were compatible with congenital dysfibrinogenemia. Occasional prolonged bleeding times were also noted. Subsequent evaluation of her parents (Table 1) revealed that she had inherited the fibrinogen abnormality from her asymptomatic father. Since 1984 the propositus has had several hospitalizations, usually for hematoma formation, frequently causing neurological compression. Platelet function evaluations made during a quiescent period demonstrated normal platelet aggregation in response to adenosine diphosphate (1×10^{-6} mol/L to 2×10^{-5} mol/L), collagen, arachidonic acid, epinephrine, and ristocetin. Analysis of plasma vWf multimers on several occasions showed an intermittent reduction of the highest-molecular weight forms. Administration of desmopressin acetate (DDAVP) did not consistently correct the bleeding time prolongation (when present) even though an increase in high-molecular weight vWf multimers was usually observed.

Table 1. Results of Laboratory Tests

Test	Propositus	Father	Mother	Normal
Plasma				
Thrombin time (s)	52.1	59.6	21.4	22.6
Reptilase time (s)	25.8	—	—	9.7
Fibrinogen, ACA (mg/dL)	50	—	—	200–400
Fibrinogen (M partigen RID) (mg/dL)	342	240	294	200–400
FDP (ng/mL)	>360	—	—	<10
Factor VIII:vW antigen (%)	110	—	—	50–150
Purified fibrinogen				
Thrombin time (s)	164	185	23	22
Coagulability with thrombin (%)	97	95	98	>95
Coagulability with reptilase (%)	68	66	—	>95
Other				
Bleeding time (min)	5–15	7.5	5	2.5-9

Abbreviations: ACA, automated chemical analysis; FDP, fibrinogen degradation products; RID, radial immuno diffusion.

Characterization of purified fibrinogen and fibrin. The thrombin time of purified propositus fibrinogen was markedly prolonged when compared with normal fibrinogen (Table 1). Thrombin clottability increased with the time of incubation and approached 100%. In the presence of reptilase, the coagulability was 68%. SDS-PAGE of Birmingham fibrinogen, fibrin, and factor XIIIa-cross-linked fibrin demonstrated that this abnormal fibrinogen contained subunit chains of normal size and XIIIa reactivity (results not shown). Similar results were obtained with her father's fibrinogen. Fibrin monomer, prepared from proband fibrinogen at physiological or at high ionic strength, polymerized at the same rate and to the same extent as did normal fibrin (results not shown).

Fibrinopeptide analysis and characterization. Total FPA (FPA plus FPA*) was released from Birmingham fibrinogen at a slower rate than that observed for normal fibrinogen (FPA $t_{1/2}$, 30 to 40 minutes v 10 minutes; Fig 1). FPB release from the abnormal fibrinogen also was moderately retarded compared with normal (FPB $t_{1/2}$, 25 and 15 minutes, respectively). Delayed FPB release accompanying slow FPA release has previously been observed in the case of fibrinogen Sydney I by Southan et al¹² who suggested that

this abnormality was due to coupled release of FPA and FPB. FPA* was first detected at later time points of the kinetic analysis (Fig 2) and was eluted with a retention time of 18.4 minutes, whereas normal FPA eluted at 19.5 minutes. This elution pattern is characteristic of that previously observed for FPA* released from fibrinogens containing an A α 16 Arg \rightarrow His substitution.^{6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16} An identical early-eluting FPA* peak was also observed with thrombin-treated fibrinogen isolated from the father's plasma.




Fig 1. Time course of fibrinopeptide release from normal and Birmingham fibrinogen. Thrombin (0.2 U/mL, final) was added to fibrinogen solutions (3 mg/mL) in 0.15 mol/L ammonium acetate buffer, pH 8.5. Top panel, normal fibrinogen; bottom panel, Birmingham fibrinogen, ●, FPA; ■, FPB; FP, fibrinopeptide; Fgn, Fibrinogen.




Fig 2. HPLC analysis of the fibrinopeptides released by thrombin from normal and Birmingham fibrinogen. Fibrinogen (3 mg/mL) was incubated with thrombin (0.2 U/mL, final) for 24 hours. Ap, phosphorylated FPA; A, FPA; Ap*, phosphorylated FPA*; A*, FPA*; Ay, FPA lacking N-terminal Ala; B-R, FPB lacking the C-terminal Arg; B, FPB.

Amino acid analysis of FPA* indicated the absence of the arginine residue found in FPA and the presence of 0.8 mol histidine/mol peptide. All other amino acids normally present in FPA were present in FPA* in the expected amounts. The carboxy-terminal sequence of FPA and FPA* was obtained from carboxypeptidase digestion. Normal FPA from the subject or the control released arginine upon CPB digestion and no amino acids with CPA. In contrast, no amino acids were released from FPA* by CPB digestion, whereas incubation with CPA resulted in the release of histidine and the penultimate valine from this peptide (results not shown).

Identification of heterodimeric Birmingham fibrinogen molecules. As expected, reptilase cleaved only FPA from normal fibrinogen. Subsequent incubation of the reptilase clot with thrombin resulted in FPB release, which accounted for all available FPB (Table 2, Fig 3A). Fibrinogen Birmingham incubated with reptilase released FPA amounting to 49% of the total FPA obtained from normal (Table 2, Fig 3B). This sample was 68% coagulable with reptilase, whereas normal was 96% coagulable. When the Birmingham reptilase clot was subsequently treated with thrombin, 45% of the FPA* and 70% of the total FPB were recovered. The remaining FPA* and FPB was recovered from the reptilase-incoagulable supernatant. As assessed by SDS-PAGE under the conditions of this experiment, fibrin cross-linking did not occur. Nearly identical results were obtained with fibrinogen isolated from the subject's father (Table 2, Fig 3C).

Table 2. Fibrinopeptide Recovery (Moles Fibrinopeptide per Mole Fibrinogen)

Sample	FPA (%)	FPA* (%)	FPB (%)
Normal fibrinogen			
Reptilase supernatant	1.92	0	0
Reptilase supernatant + IIa	0.17	0	0
Reptilase Clot + IIa	0	0	1.93
Total	2.09 (105)	0	1.93 (97)
Propositus's fibrinogen			
Reptilase supernatant	0.98 (49)	0	0
Reptilase supernatant + IIa	0.04 (2)	0.54 (27/55)	0.58 (29)
Reptilase clot + IIa	0	0.44 (22/45)	1.40 (70)
Total	1.02 (51)	0.98 (49/100)	1.98 (99)
Father's fibrinogen			
Reptilase supernatant	0.97 (49)	0	0
Reptilase supernatant + IIa	0	0.58 (29/57)	0.60 (30)
Reptilase clot + IIa	0	0.43 (22/43)	1.38 (69)
Total	0.97 (49)	1.01 (51/100)	1.98 (99)

The recovery of FPA, FPA*, and FPB was quantified by comparison of the peak area obtained from the chromatograms depicted in Fig 3 to the peak areas obtained from normal fibrinogen (3 mg/mL) treated with thrombin (10 U/mL) for two hours. HPLC analysis of samples incubated for longer periods of time indicated that complete release of all fibrinopeptides had occurred under these conditions. The proportions of FPA or FPB recovered in any given fraction is indicated, where appropriate, in parentheses as the percentage of normal; for FPA* the first number in parentheses indicates the percent recovery in relation to total fibrinopeptide A (FPA plus FPA*), whereas the second number indicates the recovery in terms of the total FPA*.




Fig 3. Comparison of fibrinopeptides released from normal and Birmingham fibrinogen. (A) Normal fibrinogen. (B) Birmingham fibrinogen (proband). (C) Birmingham fibrinogen (father). Curve 1. reptilase supernatant; curve 2. reptilase supernatant plus thrombin; curve 3, reptilase clot plus thrombin. A*, His containing A peptide; B-R, FPB lacking C-terminal Arg.

DISCUSSION

Abnormal fibrinogens that contain amino acid replacements in the amino terminal region of the A α chain make up the majority of the defects that have been determined at the molecular level.^{1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16} Fibrinogen Birmingham is an example of the commonly reported A α 16 Arg \rightarrow His substitution. Assuming that the normal and abnormal A α chain genes are transcribed and translated to the same extent and that the component chains are nonselectively assembled intracellularly to form dimeric fibrinogen molecules, one would expect hybrid molecules to amount to 50% of the circulating fibrinogen in a heterozygous individual. Homodimeric species (ie, A α , A α ; A* α , A* α) would account equally for the remainder. Our results are the first to support such an assumption. The reptilase coagulability and the distribution of FPA* and FPB in the reptilase-clotted specimens imply that hetero-dimeric species (ie, A α , A* α) comprise the theoretical 50% of circulating Birmingham fibrinogen molecules, that is, the release of nearly half of the total FPA* from the reptilase clot of both the proband's and father's fibrinogen indicates that reptilase-activated heterodimeric Birmingham fibrinogen molecules had been incorporated into the fibrin clot, evidently as the result of activation of one of its two available "A" polymerization domains. In addition, finding 69% to 70% of the total FPB in the Birmingham reptilase clot approaches the theoretical 75% that would be expected if all heterodimeric species in the Birmingham fibrinogen sample as well as all the normal molecules had been incorporated into the clot. Presumably, the reptilase clot supernatant contains the "unactivated" homodimeric (A* α , A* α) fibrinogen species plus a small proportion of "activated" hetero-dimeric molecules complexing with the soluble fibrinogen.

If, on the other hand, only homodimeric species existed in heterozygous A α 16 Arg \rightarrow His fibrinogen preparations, one would anticipate 50% coagulability with reptilase, 50% recovery of FPB from the reptilase clot, and complete recovery of available FPA* in the incoagulable supernatant of the reptilase clot. Indeed, Galanakis et al¹¹ reported 40% reptilase coagulability and no FPA* in the reptilase clot of fibrinogen Louisville, which is characterized by an A α 16 Arg — His substitution. On that basis, they concluded that only homodimeric fibrinogen molecules were present in their patient. We do not understand the biologic mechanism underlying these different findings; however, one possibility is that the hepatic mechanism of intracellular fibrinogen assembly is different in the Louisville subject as compared with ours.

Data reported on fibrinogen Kawaguchi and Osaka (A α 16 Arg \rightarrow Cys)²¹ are consistent with the existence of homodimers in these fibrinogens. Similarly, hybrid molecules were not detected in fibrinogen Seattle I (B β 14 Arg — Cys).³⁵ It seems plausible that substitution of Cys for Arg confers selectivity on the intracellular assembly process by virtue of disulfide bridging at sites that are in register. Support for the formation of disulfide bonds at the A α Cys replacement sites comes from reports on homozygous fibrinogen Metz molecules (A α 16 Arg \rightarrow Cys),^{22, 23} which have no free sulfhydryl groups and whose amino termini are evidently close enough to undergo disulfide bridging at this position.³⁶ Thus, these observations on Cys-substituted molecules do not necessarily contravene our present results suggesting that fibrinogen A α chain assembly in forming dimeric molecules is normally a nonselective process.

The bleeding episodes experienced by our subject are evidently not attributable to the A α 16 Arg \rightarrow His substitution, especially because her father is clinically normal in this regard and because other heterozygous individuals with this replacement have minimal or no bleeding tendencies.^{6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16} As assessed by analysis of her father's fibrinogen, the existence of

hybrid molecules per se appears to have little if any deleterious effect on normal hemostasis. Furthermore, it seems that a second mutation affecting the formation of fibrin is unlikely as a cause for the bleeding because fibrin monomers prepared from the proband's fibrinogen polymerized normally.

A more likely cause for the bleeding episodes is the coexistence of a second hemostatic abnormality involving either platelets or vWf. We observed an intermittent loss or absence of the highest-molecular weight multimers of vWf and occasional prolongation of the bleeding time. Platelet aggregation in the presence of various levels of ristocetin was normal, which indicated that the multimer abnormality could not be classified as a form of type IIB von Willebrand disease.^{37, 38} Even though platelet aggregation was normal, additional studies on her platelets seem warranted to investigate the possibility that her bleeding tendency could be due to storage pool deficiency.³⁹

ACKNOWLEDGMENT

We are most grateful to Dr Robert R. Montgomery for analyses of vWf, to Diane M. Bartley for her excellent technical assistance, to Betty Perrin for secretarial assistance, and to Joyce Mitchell for graphic arts.

REFERENCES

1. Beck EA: Congenital disorders of fibrin formation and stabilization, in Colman RW, Hirsh J, Marder VJ, Saltzman EW (eds): *Haemostasis and Thrombosis: Basic Principles and Clinical Practice*. Philadelphia, Lippincott, 1982, p 185
2. Henschen A, Kehl M, Southan C, Lottspeich F, Georgopoulos D. **Genetically abnormal fibrinogens—Some current characterization strategies, in.** Haverkate F, Henschen A, Nieuwenhuizen W, Straub PW (Eds.), *Fibrinogen Structure, Functional Aspects and Metabolism*, de Gruyter, Berlin (1983), p. p125
3. Galanakis DK. **Dysfibrinogenemia: A current perspective.** *Clin Lab Med*, 4 (1984), p. 395
4. Krause WH, Heene DL, Lasch HG. **Congenital dysfibrinogenemia (fibrinogen Giessen).** *Thromb Diath Haemorrh*, 29 (1973), p. 547
5. Henschen A, Alving B, Fibrinogen Giessen I. **a classical dysfibrinogen: The molecular defect, in Müller-Berghaus G, Schee-fers-Borchel U, Selmayr E, Henschen A (eds): *Fibrinogen and Its Derivatives: Biochemistry, Physiology and Pathophysiology. Proceedings of the Fibrinogen Workshop*.** New York, Elsevier (1986), p. 23.
6. Higgins DL, Shafer JA, Fibrinogen Petoskey. **a dysfibrinogenemia characterized by replacement of Arg-A α 16 by a histidyl residue.** *J Biol Chem*, 256 (1981), p. 12013
7. Higgins DL, Penner JA, Shafer JA, Fibrinogen Petoskey. **Identification of a new dysfibrinogenemia characterized by altered release of fibrinopeptide A.** *Thromb Res*, 23 (1981), p. 491
8. Southan C, Kehl M, Henschen A, Lane DA, Fibrinogen Manchester. **Identification of an abnormal fibrinopeptide A with a C-terminal arginine histidine substitution.** *Br J Haematol*, 54 (1983), p. 143
9. Lane DA, Southan C, Ireland H, Thompson E, Kehl M, Henschen A. **Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: Effect of the A α 16 Arg \rightarrow His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide.** *Br J Haematol*, 53 (1983), p. 587
10. Lane DA, van Ross M, Kakkar VV, Bottomley J, Dhir K, Holt LPJ, MacIver JE. **An abnormal fibrinogen with delayed fibrinopeptide A release.** *Br J Haematol*, 46 (1980), p. 89

11. Galanakis DK, Henschen A, Keeling M, Kehl M, Dismore RR, Peerschke EI, Fibrinogen Louisville. **An α 16 Arg \rightarrow His defect that forms no molecules in heterozygous individuals and inhibits aggregation of normal fibrin monomers.** *Ann NY Acad Sci*, 408 (1983), p. 644
12. Southan C, Lane DA, Bode W, Henschen A. **Thrombin-induced fibrinopeptide release from a variant (fibrinogen Sydney I) with an α Arg-6 \rightarrow His substitution.** *Eur J Biochem*, 147 (1985), p. 593
13. Rupp C, Sievi R, Furlan M, Beck EA, Bern II. **Fibrinogen—Erbvariante mit dem Aminosäureaustausch Argi-nin \rightarrow Histidinin Position 16 der α -kette.** *Schweiz Med Wochenschr*, 113 (1983), p. 1460
14. Ebert RF, Schreiber WE, Bell WR, Seattle II. **Congenital dysfibrinogenemia with an Arg (α 16) His substitution.** *Thromb Res*, 43 (1986), p. 7
15. Soria J, Soria C, Bertrand O, Roussel B, Dieval J, Vendrely C, Delobel J: Molecular basis for the α chain substitutions in dysfibrinogenemia with a description of two new cases of the disorder: Fibrinogen Amiens I and fibrinogen Amiens II. *Proceedings of the 1987 International Fibrinogen Workshop*. New York, Elsevier (in press)
16. Reber P, Furlan M, Beck EA, Barbui T, Fibrinogen Bergamo III. **fibrinogen Torino: Two further variants with hereditary molecular defects in fibrinopeptide A.** *Thromb Res*, 46 (1987), p. 163
17. Henschen A, Southan C, Kehl M, Lottspeich F. **The structural error and its relationship to the malfunction in some abnormal fibrinogens.** *Thromb Haemost*, 46 (1981), p. 181
18. Southan C, Henschen A, Lottspeich F: The search for structural defects in the abnormal fibrinogens, in Henschen A, Graeff H, Lottspeich F (eds): *Fibrinogen: Recent Biochemical and Medical Aspects*. New York, de Gruyter, 1982, p 153
19. Henschen A, Kehl M, Deutsch E. **Novel structure elucidation strategy for genetically abnormal fibrinogens with incomplete fibrinopeptide release as applied to fibrinogen Schwarzach.** *Hoppe Seylers Z Physiol Chem*, 364 (1983), p. 1747
20. Reber P, Furlan M, Beck EA, Finazzi G, Buelli M, Barbui T. **Bergamo I (α 16 arg cys): Susceptibility towards thrombin following aminoethylation, methylation or carboxamido-methylation of cysteine residues.** *Thromb Haemost*, 54 (1985), p. 390
21. Matsuda M, Terukina S, Miyata T, Iwanaga S. **Defective release of fibrinopeptide A due to substitution of α arginine-16 by cysteine in two abnormal fibrinogens Kawaguchi and Osaka,** in: G Muller-Berghaus, U Scheefers-Borchel, E Selmayr, A Henschen (Eds.), *Fibrinogen and Its Derivatives: Biochemistry, Physiology and Pathophysiology, Proceedings of the Fibrinogen Workshop*, Elsevier, New York (1986), p. 37
22. Soria J, Soria C, Samama C, Poirot E, Kling C. **Fibrinogen Troyes—fibrinogen Metz. Two new cases of congenital dysfibrinogenemia.** *Thromb Diath Haemorrh*, 27 (1972), p. 619
23. Soria J, Soria C, Samama M, Henschen A, Southan C. **Detection of fibrinogen abnormality in dysfibrinogenemia: Special report of fibrinogen Metz characterization by an amino acid substitution located at the peptide bond cleaved by thrombin, in.** A Henschen, H Graeff, F Lottspeich (Eds.), *Fibrinogen: Recent Biochemical and Medical Aspects*, de Gruyter, New York (1982), p. 129
24. Kazal LA, Amsel S, Miller OP, Tocantins LM. **The preparation and some properties of fibrinogen precipitated from human plasma by glycine.** *Proc Soc Exp Biol Med*, 113 (1963), p. 989
25. Mosesson MW, Sherry S. **The preparation and properties of human fibrinogen of relatively high solubility.** *Biochemistry*, 5 (1966), p. 2829
26. Mosesson MW, Finlayson JS. **Subfractions of human fibrinogen—Preparation and analysis.** *J Lab Clin Med*, 62 (1963), p. 663
27. Montgomery RR, Hathaway WE, Johnson J, Jacobson L, Muntean W. **A variant of von Willebrand's disease with abnormal expression of factor VIII procoagulant activity.** *Blood*, 60 (1982), p. 201

28. Laki K. **The polymerization of proteins: The action of thrombin on fibrinogen.** *Arch Biochem Biophys*, 32 (1951), p. 317
29. Laemmli UK. **Cleavage of structural proteins during the assembly of the head of bacteriophage T4.** *Nature*, 227 (1970), p. 680
30. Kehl M, Lottspeich F, Henschen A. **Analysis of human fibrinopeptides by high performance liquid chromatography.** *Hoppe Seylers Z Physiol Chem*, 362 (1981), p. 1661
31. Kehl M, Henschen A. **Characterization of the peptides released at the fibrinogen-fibrin conversion using high performance liquid chromatography, in.** F Lottspeich, A Henschen, K-P Hupe (Eds.), *HPLC in Protein and Peptide Chemistry*, de Gruyter, New York (1981), p. 339
32. Belitser VA, Varetskaja TV, Malneva GV. **Fibrinogen-fibrin interaction.** *Biochim Biophys Acta*, 154 (1968), p. 367
33. Gralnick HR, Givelber HM, Shainoff JR, Finlayson JS, Fibrinogen Bethesda. **A congenital dysfibrinogenemia with delayed fibrinopeptide release.** *J Clin Invest*, 50 (1971), p. 1819
34. Benson RE, Hare PE. **Ophthalaldehyde: Fluorogenic detection of primary amines in the picomole range. Comparison with fluorescamine and ninhydrin.** *Proc Natl Acad Sci USA*, 72 (1975), p. 619
35. Pirkle H, Kaydewitz H, Henschen A, Theodor I: Substitution of B β 14 arginine by cyst(e)ine in fibrinogen Seattle I. *Proceedings of the 1987 Fibrinogen International Workshop*. Elsevier, New York (in press)
36. Mosesson MW, Siebenlist KR, DiOrio JP, Hainfeld JF, Wall JS, Soria J, Soria C, Samama M. **Evidence that proximal NH₂-terminal portions of fibrinogen Metz (Aa 16 Arg→Cys) Aa chains are oriented in the same direction, in.** G Muller-Berghaus, U Scheefers-Borchel, E Selmayr, A Henschen (Eds.), *Fibrinogen and Its Derivatives: Biochemistry, Physiology and Pathophysiology. Proceedings of the Fibrinogen Workshop*, Elsevier, New York (1986), p. 3
37. Hoyer LW. **The factor VIII complex: Structure and function.** *Blood*, 58 (1981), p. 1
38. Zimmerman TS, Ruggeri ZM, Fulcher CA. **Factor VIII/von Willebrand factor, in.** EB Brown (Ed.), *Progress in Hematology*, Grune & Stratton, Philadelphia (1983), p. 279
39. Nieuwenhuis HK, Sixma JJ. **Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: Studies on 106 patients.** *Blood*, 70 (1987), p. 620